A Phase I, Open Label Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC647055 Given in Combination With Telaprevir
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2014
At a glance
- Drugs TMC 647055 (Primary) ; Peginterferon alfa; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Janssen R&D Ireland
- 14 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2013 Planned end date changed from 1 May 2014 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 18 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.